fda glp-1 safety warning september 2025 compounding letters Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded Drugs and Telehealth Providers Beyond the Headlines: FDA Warning – Alarming rise in weight loss

Design and Biosynthesis of Ornithine 8-Containing Semaglutide Variants with a Click [PMID: 40305415] Laboratory literature summary: Design and Biosynthesis of Ornithine 8-Containing Semaglutide Variants with a Click Chemistry-Modifiable Position 26

15,20 Serious GI AEs, though uncommon, have also been reported with GLP-1 RA therapy, including gastroparesis, intestinal obstruction, pancreatitis, and colonic ischemia

This weekly dosing schedule offers a streamlined and convenient option for patients, removing the need for daily injections while maintaining consistent therapeutic benefits

Ready to level up your recovery and daily wellness